flufenamic acid has been researched along with Disease Models, Animal in 14 studies
Flufenamic Acid: An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically. (From Martindale, The Extra Pharmacopoeia, 30th ed, p16)
flufenamic acid : An aromatic amino acid consisting of anthranilic acid carrying an N-(trifluoromethyl)phenyl substituent. An analgesic and anti-inflammatory, it is used in rheumatic disorders.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Epilepsy is one of the most common neurologic diseases, and around 30% of all epilepsies, particularly the temporal lobe epilepsy (TLE), are highly refractory to current pharmacological treatments." | 5.91 | A Single High Dose of Flufenamic Acid in Rats does not Reduce the Damage Associated with the Rat Lithium-Pilocarpine Model of Status Epilepticus but Leads to Deleterious Outcomes. ( Bascuñana, P; Delgado, M; García-García, L; Gomez, F; Hernández-Martín, N; Pozo, MÁ; Rosa, RF; Silván, Á, 2023) |
| "Flufenamic acid (FFA) has previously been demonstrated to be a potent activator of AMP-activated protein kinase (AMPK), which is a negative regulator of NF-κB signaling." | 5.46 | Flufenamic acid protects against intestinal fluid secretion and barrier leakage in a mouse model of Vibrio cholerae infection through NF-κB inhibition and AMPK activation. ( Chatsudthipong, V; Chittavanich, P; Kittayaruksakul, S; Muanprasat, C; Pongkorpsakol, P; Satitsri, S; Srimanote, P; Wongkrasant, P, 2017) |
| "Epilepsy is one of the most common neurologic diseases, and around 30% of all epilepsies, particularly the temporal lobe epilepsy (TLE), are highly refractory to current pharmacological treatments." | 1.91 | A Single High Dose of Flufenamic Acid in Rats does not Reduce the Damage Associated with the Rat Lithium-Pilocarpine Model of Status Epilepticus but Leads to Deleterious Outcomes. ( Bascuñana, P; Delgado, M; García-García, L; Gomez, F; Hernández-Martín, N; Pozo, MÁ; Rosa, RF; Silván, Á, 2023) |
| "Postmenopausal osteoporosis is one of the most common types of osteoporosis resulting from estrogen deficiency in elderly women." | 1.56 | Flufenamic acid inhibits osteoclast formation and bone resorption and act against estrogen-dependent bone loss in mice. ( Huo, S; Li, H; Nie, B; Qu, X; Tang, H; Yue, B; Zhang, S, 2020) |
| "Flufenamic acid (FFA) has previously been demonstrated to be a potent activator of AMP-activated protein kinase (AMPK), which is a negative regulator of NF-κB signaling." | 1.46 | Flufenamic acid protects against intestinal fluid secretion and barrier leakage in a mouse model of Vibrio cholerae infection through NF-κB inhibition and AMPK activation. ( Chatsudthipong, V; Chittavanich, P; Kittayaruksakul, S; Muanprasat, C; Pongkorpsakol, P; Satitsri, S; Srimanote, P; Wongkrasant, P, 2017) |
| "Anandamide (AEA) is an endocannabinoid (EC) that modulates multiple functions in the CNS and that is released in areas of injury, exerting putative neuroprotective actions." | 1.42 | Endocannabinoids regulate the activity of astrocytic hemichannels and the microglial response against an injury: In vivo studies. ( Cravatt, BF; Hillard, CJ; Koester, EC; Moreno, M; Pazos, MR; Romero, J; Tolón, RM; Vázquez, C, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Sellitto, C | 1 |
| Li, L | 1 |
| White, TW | 1 |
| Hernández-Martín, N | 1 |
| Gomez, F | 1 |
| Silván, Á | 1 |
| Rosa, RF | 1 |
| Delgado, M | 1 |
| Bascuñana, P | 1 |
| Pozo, MÁ | 1 |
| García-García, L | 1 |
| Zhang, S | 1 |
| Huo, S | 1 |
| Li, H | 1 |
| Tang, H | 1 |
| Nie, B | 1 |
| Qu, X | 1 |
| Yue, B | 1 |
| Spray, DC | 1 |
| Iglesias, R | 1 |
| Shraer, N | 1 |
| Suadicani, SO | 1 |
| Belzer, V | 1 |
| Hanstein, R | 1 |
| Hanani, M | 1 |
| Vázquez, C | 1 |
| Tolón, RM | 1 |
| Pazos, MR | 1 |
| Moreno, M | 1 |
| Koester, EC | 1 |
| Cravatt, BF | 1 |
| Hillard, CJ | 1 |
| Romero, J | 1 |
| Pongkorpsakol, P | 1 |
| Satitsri, S | 1 |
| Wongkrasant, P | 1 |
| Chittavanich, P | 1 |
| Kittayaruksakul, S | 1 |
| Srimanote, P | 1 |
| Chatsudthipong, V | 1 |
| Muanprasat, C | 1 |
| Nakamura, H | 1 |
| Motoyoshi, S | 1 |
| Imazu, C | 1 |
| Ishii, K | 1 |
| Yokoyama, Y | 1 |
| Seto, Y | 1 |
| Kadokawa, T | 1 |
| Shimizu, M | 1 |
| Wax, J | 2 |
| Tessman, DK | 1 |
| Winder, CV | 2 |
| Stephens, MD | 1 |
| Mörsdorf, K | 1 |
| Anspach, K | 1 |
| Mizushima, Y | 1 |
| Tsukada, W | 1 |
| Akimoto, T | 1 |
| Wawrzyńska-Pagowska, J | 1 |
| Beck, FW | 1 |
| Whitehouse, MW | 1 |
| Clinger, WA | 1 |
| Varner, P | 1 |
| Bass, P | 1 |
1 review available for flufenamic acid and Disease Models, Animal
| Article | Year |
|---|---|
[Clinical use of non-steroid anti-inflammatory agents].
Topics: Animals; Anti-Inflammatory Agents; Antigen-Antibody Complex; Arthritis, Rheumatoid; Aspirin; Cell Mi | 1974 |
13 other studies available for flufenamic acid and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Connexin hemichannel inhibition ameliorates epidermal pathology in a mouse model of keratitis ichthyosis deafness syndrome.
Topics: Animals; Connexin 26; Disease Models, Animal; Epidermis; Flufenamic Acid; Keratitis; Mice, Transgeni | 2021 |
A Single High Dose of Flufenamic Acid in Rats does not Reduce the Damage Associated with the Rat Lithium-Pilocarpine Model of Status Epilepticus but Leads to Deleterious Outcomes.
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Epilepsy; Epilepsy, Temporal Lobe; Flufen | 2023 |
Flufenamic acid inhibits osteoclast formation and bone resorption and act against estrogen-dependent bone loss in mice.
Topics: Animals; Anti-Inflammatory Agents; Bone Density; Bone Resorption; Cell Differentiation; Disease Mode | 2020 |
Gap junction mediated signaling between satellite glia and neurons in trigeminal ganglia.
Topics: Animals; Boron Compounds; Carbenoxolone; Cells, Cultured; Disease Models, Animal; Female; Flufenamic | 2019 |
Endocannabinoids regulate the activity of astrocytic hemichannels and the microglial response against an injury: In vivo studies.
Topics: Adenosine Triphosphate; Amides; Amidohydrolases; Animals; Anti-Inflammatory Agents; Apyrase; Arachid | 2015 |
Flufenamic acid protects against intestinal fluid secretion and barrier leakage in a mouse model of Vibrio cholerae infection through NF-κB inhibition and AMPK activation.
Topics: AMP-Activated Protein Kinases; Animals; Body Fluids; Calcium-Calmodulin-Dependent Protein Kinase Kin | 2017 |
[Anti-inflammatory, analgesic and anti-pyretic activities of a non-steroidal anti-inflammatory drug, etofenamate, in experimental animals].
Topics: Analgesics; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, E | 1982 |
A sensitive method for the comparative bioassay of nonsteroidal anti-inflammatory compounds in adjuvant-induced primary inflammation in the rat.
Topics: Aminopyrine; Analysis of Variance; Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin | 1975 |
[Efficacy of different antiphlogistic agents with respect to carrageenan-inflammation, compared with other models of inflammation].
Topics: Adrenocorticotropic Hormone; Aminopyrine; Animals; Anti-Inflammatory Agents; Aspirin; Carrageenan; D | 1971 |
A modification of rat adjuvant arthritis for testing antirheumatic drugs.
Topics: Adjuvants, Immunologic; Aminopyrine; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Arthr | 1972 |
I. Drug sensitivity of rat adjuvant arthritis, induced with "adjuvants" containing no mineral oil components.
Topics: Animals; Arthritis; Aspirin; Disease Models, Animal; Flufenamic Acid; Freund's Adjuvant; Lipids; Mal | 1974 |
Relationship of the enterohepatic cycle to ulcerogenesis in the rat small bowel with flufenamic acid.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Bile Ducts, Intrahepatic; Cholestyramine Re | 1970 |